DEC has been interested for some time, and now IBM is going into the computer-aided drugs design business by taking an undisclosed stake in privately-held Polygen Corp, Waltham, Massachusetts as part of an agreement under which Polygen will devel-op versions of its applications for the chemical and pharmaceutical industries for use on IBM’s mainframes and […]
DEC has been interested for some time, and now IBM is going into the computer-aided drugs design business by taking an undisclosed stake in privately-held Polygen Corp, Waltham, Massachusetts as part of an agreement under which Polygen will devel-op versions of its applications for the chemical and pharmaceutical industries for use on IBM’s mainframes and workstations.
